Follow Insulet to never miss an important update.
After Insulet reported its November results, we updated our fair value and cut our quality score to 4.0. We added a new section to our thesis to track the risks from manufacturing lawsuits and the cost of fixing medical device defects. We also added the company's new plan to spend one billion dollars buying its own shares to what we monitor. Our projections now assume higher profit margins and slightly slower sales growth in the United States.
Insulet earned $1.99 per share this quarter, well ahead of the $1.59 analysts expected. Revenue reached $842 million, led by a 33 percent jump in international sales. This growth shows that the company's tubeless "patch pump," which is worn on the skin and controlled by a smartphone, is winning over patients in new markets who are moving away from traditional insulin injections.
Profitability also improved significantly, with operating income, the profit left after paying for the daily costs of running the business, rising to 22.5 percent of revenue. The stock rose about 5 percent following the report. This performance supports the view that Insulet can maintain high margins even as it spends to expand its manufacturing and reach more people with type 2 diabetes.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Insulet is scheduled to share its latest financial results on November 4. Analysts are looking for revenue of about 830 million dollars and earnings of 1.59 dollars per share. The report will provide an update on how quickly the company is expanding into the type 2 diabetes market, which is a key part of its growth plan.
Jefferies analysts kept their buy rating on the stock this week. They set a target price of $190, which is well above the current price of about $136. This reflects a view that the company's tubeless insulin pumps will continue to win over patients from traditional tubed systems. The average target among all analysts who follow the company is now about $183. While these targets are just estimates of where the stock might trade in a year, the gap between the current price and these targets shows that many analysts believe the business is worth significantly more than its recent market price suggests.
Source: Jefferies
Insulet has launched Omnipod Discover, a software platform that turns data from its wearable insulin pumps into charts and insights for patients and doctors. The tool is designed to make it easier for healthcare providers to see how a patient is managing their diabetes and make adjustments to their treatment.
This launch is a move to make Insulet's hardware more useful by surrounding it with better software. By making the data easier to read and share, the company makes its system more valuable to doctors, who are the ones who ultimately recommend which pump a patient should use.
Source: Business Wire
Management has cleared its own profit targets for eight straight quarters, often by wide margins. This suggests the business is outrunning its own forecasts as it scales up production.
| Expectation | |
|---|---|
| EPS | $1.74 |
| Revenue | $900M |